Didier Georges

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

DNAVision SA operates as a research and development company. The firm provides genomic services to the pharmaceutical, food and biotechnology industries. It offers Non-Executive Directortgen seqencing, bioinformatics, sanger sequence, expression profiling, DNA extraction and biobanking. The company was founded in May 2004 and is headquartered in Charleroi, Belgium.

Aliwen, a Université Libre de Bruxelles spin-off company, provides new methods and technologies in the area of plant physiology and urban trees management for public and private institutions. The Tree Study Centre offers a broad range of services for public and private green areas managers. Its tree doctors' team provides the best solutions for optimizing urban trees day-to-day management. The Agrotechnologies Centre provides state-of the-art services relying on an experienced scientific staff and innovative technologies in order to solve plant-related problems in the agriculture and environment sector.

H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US.

Biopole ULB Charleroi SA provides space for companies. The firm offers services to academic and industrial research teams belonging to Biopark Charleroi Brussels South. It serves the administrative, logistical, and applied technology sectors. The company was founded in 2003 and is headquartered in Charleroi, Belgium.

Advanced Engineering Accelerator SA provides business support services for engineering firms. The company is based in Charleroi, Belgium. The CEOs are Olivier Belenger, Maxime Vuckovic. The Belgian company was founded in 2018.

E-Health Venture NV is an incubator and studio for startups and scale-ups in e-health. The company is based in Anderlecht, Belgium. The Belgian company's network provides start-ups with critical access to customers, funding, strategic coaching, and operational support. The company was founded in 2018 and empowers forward-looking individuals and organizations in healthcare by nurturing innovation within an ecosystem of partners with a range of expertise.